

---

Press Release May 15<sup>th</sup> 2008

## **VEMEDIA ACQUIRES VALDISPERT FROM SOLVAY PHARMACEUTICALS AND BECOMES A EUROPEAN PHARMA/OTC PLAYER**

Vemedia acquires Valdispert/Baldrian valerian root extract tablets, indicated in the treatment of mild to moderate sleeping disorders and states of restlessness and tension. Solvay Pharmaceuticals divests all rights to manufacture and market the products in all territories around the world to Vemedia.

To finance this transaction, Vemedia Pharma will increase its capital with 4,5 million Euro, which will be subscribed by existing shareholders ( i.a. Indufin and Leeuward Ventures Sicar ), completed by mezzanine- (KBC Private Equity, Indufin ) and bank loans (Dexia, KBC bank and Rabobank).

Valdispert / Baldrian are well –known brand names. They are one of the leaders in sedative plant extracts and sales are well established in Germany, Belgium, the Netherlands, Italy, Portugal and Spain, Greece and some other smaller markets.

Valdispert / Baldrian are approved medicinal products and are exclusively distributed through pharmacies.

Vemedia's Chief Executive Officer Yvan Vindevogel says: "Vemedia and Solvay Pharmaceuticals share a long and successful history with Valdispert in the Netherlands, and both parties are delighted that the Valdispert / Baldrian products will remain in good hands. Vemedia is pleased to be able to grow the brand in the future in different European countries, where Vemedia is going to establish its own marketing structures in the coming years, enabling to launch its other products in those countries. Vemedia is now a European Pharma /OTC-player. The acquisition of Valdispert is exactly in line with the long term strategy that Vemedia has worked out, by acquiring top brands in the OTC field."

Vemedia also takes over the OTC sales-structure of Solvay Pharmaceuticals in Spain, and will distribute the remaining Spanish Solvay OTC- products.

About Vemedia :

Vemedia B.V. was established in the 60-ties and became part of Solvay Pharmaceuticals B.V. in the Netherlands. In 1983 Solvay Pharmaceuticals transferred its activities in the fields of self-care medication ( OTC products ), and health products to Vemedia B.V. That company was sold in 2002 by Solvay to Vemedia Pharma N.V., part of the independent Vemedia Group. The Vemedia Group now is a leading concern in self-care medication, health products , pharmaceutical ingredients, and insecticides in the Netherlands and Belgium. For more information, visit [www.vemediapharma.com](http://www.vemediapharma.com).

For additional questions about this acquisition, please contact one of the following persons:

Yvan Vindevogel      CEO      +32 (0) 475 453 320

Rob Drenth            COO      +31 (0) 205 198 203

Jean-Yves De Vel    CFO      +32 (0) 476 495 025